ROCO
4132
Market cap19mUSD
Apr 09, Last price
3.47TWD
Name
Golden Biotechnology Corp
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Golden Biotechnology Corporation, founded in 2002 and based in New Taipei City, Taiwan, is engaged in both pharmaceutical drug discovery and the production of health-enhancing dietary supplements. The company operates internationally, serving markets in Taiwan, the United States, Japan, China, Korea, and Singapore. Its varied product line includes several health supplements: Liverty, formulated to support liver function and help alleviate fatigue. Rasle, which serves as an adjunctive therapy for autoimmune conditions. ZSAINO, a nutritional product designed to aid recovery from illness and boost general well-being. UMOOZE, a specialized herbal blend targeting optimal health for men. Furthermore, Golden Biotechnology is developing Antroquinonol, an anticancer molecule. This compound is currently utilized in the treatment of severe conditions such as pancreatic cancer, acute myeloid leukemia, and hepatocellular carcinoma, in addition to addressing hypercholesterolemia and hyperlipidemia.
Key people
Sheng-Yung Liu
Chairman of the Board · since 2022
Yuqun Chen
Vice Chairman of the Board · since 2013
Guosheng Lin
Chief Financial Officer, Head of Finance · since 2023
Wenjian Cai
General Manager · since 2022
Zhiyuan Chen
Deputy General Manager-Management Division · since 2014
Shingo Horii
Deputy General Manager-International Business Division · since 2018
Ruiwen Nian
Deputy General Manager-Chairman's Office · since 2010
Wuzhe Wen
Deputy General Manager-Research & Development Division · since 2006
Fengren Wu
Deputy General Manager-Information Marketing Division · since 2016
Haoyu Zheng
Deputy General Manager-Clinical Medicine Research Division · since 2009
Chenghan Dai
Manager of Accounting · since 2024
Director · since 2017
Jinghua Wang
Director · since 2025
Liyu Wu
President, Director · since 2002
Xinghao Xu
Director · since 2020
Shiqi Huang
Independent Director · since 2025
Zhenji Wu
Independent Director · since 2025
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | ||||||
Revenues | ||||||
Cost of revenue | ||||||
Unusual Expense (Income) | ||||||
NOPBT | ||||||
NOPBT Margin | ||||||
Operating Taxes | ||||||
Tax Rate | ||||||
NOPAT | ||||||
Net income | ||||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | ||||||
BB yield | ||||||
| Debt | ||||||
Debt current | ||||||
Long-term debt | ||||||
Deferred revenue | ||||||
Other long-term liabilities | ||||||
Net debt | ||||||
| Cash flow | ||||||
Cash from operating activities | ||||||
CAPEX | ||||||
Cash from investing activities | ||||||
Cash from financing activities | ||||||
FCF | ||||||
| Balance | ||||||
Cash | ||||||
Long term investments | ||||||
Excess cash | ||||||
Stockholders' equity | ||||||
Invested Capital | ||||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | ||||||
Price | ||||||
Market cap | ||||||
EV | ||||||
EBITDA | ||||||
EV/EBITDA | ||||||
Interest | ||||||
Interest/NOPBT | ||||||